International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 5 , Pages 1315-1321 , 1 August 2010

Young Men Have Equivalent Biochemical Outcomes Compared With Older Men After Treatment With Brachytherapy for Prostate Cancer

  • Ryan J. Burri, M.D.

      Affiliations

    • Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York
    • ,
  • Alice Y. Ho, M.D.

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Kevin Forsythe, M.D.

      Affiliations

    • Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York
    • ,
  • Jamie A. Cesaretti, M.D.

      Affiliations

    • Florida Radiation Oncology Group, Jacksonville, Florida
    • ,
  • Nelson N. Stone, M.D.

      Affiliations

    • Department of Urology, Mount Sinai School of Medicine, New York, New York
    • ,
  • Richard G. Stock, M.D.

      Affiliations

    • Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York
    • Corresponding Author InformationReprint requests to: Richard G. Stock, M.D., Department of Radiation Oncology, Box 1236, 1 Gustave L. Levy Place, New York, NY 10029. Tel: (212) 241-7500; Fax: (212) 410-7194

Received 22 May 2009 ,Revised 22 June 2009 ,Accepted 24 June 2009.

References 

  1. Alibhai SM, Krahn MD, Cohen MM, et al. Is there age bias in the treatment of localized prostate carcinoma?. Cancer. 2004;100:72–81
  2. Merglen A, Schmidlin F, Fioretta G, et al. Short- and long-term mortality with localized prostate cancer. Arch Intern Med. 2007;167:1944–1950
  3. National Comprehensive Cancer Network. Prostate cancer, practice guidelines in oncology v.2.2009. 2009.
  4. In:  Beahrs OH,  Henson DE,  Hutter RVP editor. Manual for staging of cancer. 4th ed. Philadelphia: J.B. Lippincott; 1992;
  5. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  6. Stock RG, Stone NN, Wesson MF, et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys. 1995;32:219–225
  7. Stone NN, Ramin SA, Wesson MF, et al. Laparoscopic pelvic lymph node dissection combined with real-time interactive transrectal ultrasound guided transperineal radioactive seed implantation of the prostate. J Urol. 1995;153:1555–1560
  8. Stone NN, Stock RG. Prostate brachytherapy: treatment strategies. J Urol. 1999;162:421–426
  9. Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys. 2002;52:444–452
  10. Potters L, Cao Y, Calugaru E, et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2001;50:605–614
  11. Stock RG, Stone NN, Lo YC, et al. Postimplant dosimetry for (125)I prostate implants: definitions and factors affecting outcome. Int J Radiat Oncol Biol Phys. 2000;48:899–906
  12. Stock RG, Stone NN, Tabert A, et al. A dose–response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998;41:101–108
  13. Beyer D, Nath R, Butler W, et al. American brachytherapy society recommendations for clinical implementation of NIST-1999 standards for (103)palladium brachytherapy. The clinical research committee of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys. 2000;47:273–275
  14. Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys. 1995;22:209–234
  15. Stock RG, Stone NN, Cesaretti JA, et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys. 2006;64:527–533
  16. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  17. Stock RG, Stone NN, Iannuzzi C. Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 1996;35:267–272
  18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  19. Beck M. Prostate cancer: Weighing options. The Wall Street Journal. 2009;p. B9
  20. Merrick GS, Butler WM, Wallner KE, et al. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Urology. 2004;64:754–759
  21. Nguyen TD, Poortmans PM, van der Hulst M, et al. The curative role of radiotherapy in adenocarcinoma of the prostate in patients under 55 years of age: A rare cancer network retrospective study. Radiother Oncol. 2005;77:286–289
  22. Peschel RE, Khan A, Colberg J, et al. The effect of age on prostate implantation results. Cancer J. 2006;12:305–308
  23. Rosser CJ, Chichakli R, Levy LB, et al. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation. J Urol. 2002;168:536–541
  24. Rossi CJ, Slater JD, Yonemoto LT, et al. Influence of patient age on biochemical freedom from disease in patients undergoing conformal proton radiotherapy of organ-confined prostate cancer. Urology. 2004;64:729–732
  25. Shapiro EY, Rais-Bahrami S, Morgenstern C, et al. Long-term outcomes in younger men following permanent prostate brachytherapy. J Urol. 2009;181:1665–1671discussion 1671
  26. Magheli A, Rais-Bahrami S, Humphreys EB, et al. Impact of patient age on biochemical recurrence rates following radical prostatectomy. J Urol. 2007;178:1933–1937discussion 1937–1938
  27. Richstone L, Bianco FJ, Shah HH, et al. Radical prostatectomy in men aged >or = 70 years: Effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram. BJU Int. 2008;101:541–546
  28. Rosser CJ, Kamat AM, Wang X, et al. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with radical prostatectomy. Urology. 2006;67:769–773
  29. Tward JD, Lee CM, Pappas LM, et al. Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: Impact of age at diagnosis. Cancer. 2006;107:2392–2400
  30. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8:475–487
  31. Ho AY, Burri RJ, Cesaretti JA, et al. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2009;In press
  32. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74
  33. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized Phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24:1990–1996
  34. Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol. 2005;23:1192–1199
  35. Shipley WU, Verhey LJ, Munzenrider JE, et al. Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys. 1995;32:3–12
  36. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA. 2005;294:1233–1239
  37. Cesaretti JA, Kao J, Stone NN, et al. Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: Analysis at > or = 7 years of follow-up. BJU Int. 2007;100:362–367
  38. Finney G, Haynes AM, Cross P, et al. Cross-sectional analysis of sexual function after prostate brachytherapy. Urology. 2005;66:377–381
  39. Macdonald AG, Keyes M, Kruk A, et al. Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: Is dose to the penile bulb important?. Int J Radiat Oncol Biol Phys. 2005;63:155–163
  40. Sanchez-Ortiz RF, Broderick GA, Rovner ES, et al. Erectile function and quality of life after interstitial radiation therapy for prostate cancer. Int J Impot Res. 2000;12(Suppl. 3):S18–24
  41. Abdel-Wahab M, Reis IM, Hamilton K. Second primary cancer after radiotherapy for prostate cancer—a seer analysis of brachytherapy versus external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72:58–68
  42. Brenner DJ, Curtis RE, Hall EJ, et al. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer. 2000;88:398–406
  43. Moon K, Stukenborg GJ, Keim J, et al. Cancer incidence after localized therapy for prostate cancer. Cancer. 2006;107:991–998
  44. Pickles T, Phillips N. The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984–2000. Radiother Oncol. 2002;65:145–151
  45. Kendal WS, Eapen L, Macrae R, et al. Prostatic irradiation is not associated with any measurable increase in the risk of subsequent rectal cancer. Int J Radiat Oncol Biol Phys. 2006;65:661–668
  46. Movsas B, Hanlon AL, Pinover W, et al. Is there an increased risk of second primaries following prostate irradiation?. Int J Radiat Oncol Biol Phys. 1998;41:251–255
  47. Fontenot JD, Lee AK, Newhauser WD. Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74:616–622
  48. Takam R, Bezak E, Yeoh EE. Risk of second primary cancer following prostate cancer radiotherapy: DVH analysis using the competitive risk model. Phys Med Biol. 2009;54:611–625
  49. Liauw SL, Sylvester JE, Morris CG, et al. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. Int J Radiat Oncol Biol Phys. 2006;66:669–673
  50. USPSTF. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:185–191
  51. Andriole GL, Grubb RL, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–1319
  52. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–1328

 Conflict of interest: J. A. Cesaretti is a consultant to C.R. Bard. N. N. Stone is owner of Prologics LLC and a consultant to Nihan Medi-Physics and B & K Medical. The other authors report no conflicts of interest.

PII: S0360-3016(09)01000-1

doi: 10.1016/j.ijrobp.2009.06.052

International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 5 , Pages 1315-1321 , 1 August 2010

Article Tools

* Image Usage & Resolution